News & Comment

Filter By:

Article Type
Year

  • Wayne Koff, Chief Scientific Officer at the International AIDS Vaccine Initiative, discusses the imminent launch of the Human Vaccines Project.

    An Audience With

  • Doug Williams, head of Research and Development at Biogen Idec, discusses remyelinating agents, Alzheimer's disease drugs and gene therapy.

    An Audience With

  • Keith Blundy, Chief Executive Officer of Cancer Research Technology, discusses new developments at the non-profit Cancer Research UK.

    An Audience With

  • Story Landis, ex-Director of the US National Institute of Neurological Disorders and Stroke, discusses how she has worked to address a crisis of basic research funding at the Institute.

    An Audience With

  • Bob More, venture capitalist with the Bill and Melinda Gates Foundation, discusses the challenges of aligning financial and philanthropic interests.

    An Audience With

  • Steve Blank, a serial entrepreneur, discusses the need for more focus on commercialization at even the earliest stages of a startups life cycle.

    An Audience With

  • Tatsuya Kondo, chief executive of the PMDA, discusses the tenth anniversary of the Japanese regulatory authority.

    An Audience With

  • The FDA's Tatiana Prowell discusses some of the most common pitfalls in oncology drug development.

    An Audience With

  • John P. A. Ioannidis, Professor of Medicine, Health Research and Policy and Statistics at Stanford University, discusses his latest plans to tackle irreproducibility in science.

    An Audience With

  • Wolfgang Plischke, Bayer's outgoing chief of innovation, discusses R&D funding and the intersection of human, animal and plant research.

    An Audience With

  • John Reed, Head of Pharma Research & Early Development at Roche, discusses his plans to tweak the therapeutic focus, clinical development strategy and externalization of innovation at Roche.

    An Audience With

  • Mads Krogsgaard Thomsen celebrates his twentieth anniversary of overseeing R&D at Novo Nordisk.

    An Audience With